Biotech

All Articles

Amgen files 1st period 3 gain for $400M dermatitis drug

.Amgen has shared (PDF) the very first phase 3 information on its own $400 thousand eczema medicatio...

Biogen, UCB report period 3 lupus succeed after falling short earlier test

.Biogen and UCB's gamble on improving into phase 3 astride a failed research seeks to have paid, alo...

Aptadir hopes brand new RNA inhibitors can turn around tricky cancers cells

.Italian biotech Aptadir Rehabs has released along with the commitment that its pipe of preclinical ...

Wave surfs DMD success to regulatory authorities' doors, sending out stock up

.Wave Life Sciences has actually met its goal in a Duchenne muscular dystrophy (DMD) research, placi...

Sanofi picks new CSO coming from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma fold, using ...

Achilles droplets tissue treatment system, bandages for unemployments after missing out on 'industrial stability' objectives

.Achilles Therapeutics has actually torn up its own method. The British biotech is actually quiting ...

Aligos advertises period 2 MASH succeed, slashing liver fat approximately 46%

.Aligos Therapies is actually proclaiming a midstage win in metabolic-dysfunction connected steatohe...

Basilea ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's job establishing brand new antifungals has actually received a significant ...

Capricor offers Europe civil liberties to late-stage DMD therapy for $35M

.Possessing actually scooped up the U.S. rights to Capricor Therapies' late-stage Duchenne muscle dy...

FDA fragments adcomm for Applied's rare ailment drug

.After dismissing the selection date for Applied Therapeutics' metabolic disorder drug govorestat, t...